== Overview ofin vitroandin vivomodels for hepatitis C virus HCVpp: Hepatitis C virus (HCV) pseudotyped viral particles; VLP: Virus like particle; HCVcc: Cell culture derived HCV. Defeated by classical approaches to isolate HCV, virologists were forced to reproduce the HCV lifecycle using split models, which included the HCV genome RNA replication model (HCV replicon)[15,16], HCV structural proteins model (virus-like particle, VLP)[52] and HCV pseudotyped viral particles model[17] (Table1). culture, researchers have had to avail themselves to the best of modern biomedical technology; some of the major achievements in HCV research have not only advanced the understanding of HCV but also promoted knowledge of virology and cellular physiology. In this review, we summarize the advancements and remaining scotomas in the molecular virology and epidemiology of HCV. Keywords:Hepatitis C virus, Hepatitis C virus lifecycle, Molecular virology, Hepatitis C virus models, Epidemiology Core tip:The review summarizes the advancements, as well as remaining scotomas, in the molecular virology of hepatitis C virus (HCV). We emphasize the contributions of HuH-7 hepatocellular carcinoma cell line to development of the Mouse monoclonal antibody to Hexokinase 2. Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in mostglucose metabolism pathways. This gene encodes hexokinase 2, the predominant form found inskeletal muscle. It localizes to the outer membrane of mitochondria. Expression of this gene isinsulin-responsive, and studies in rat suggest that it is involved in the increased rate of glycolysisseen in rapidly growing cancer cells. [provided by RefSeq, Apr 2009] HCV replicon, cell culture-derived HCV, Tarafenacin D-tartrate and HCV pseudoparticles. In addition, we reiterate the importance of epidemiological issues because accurate assessment of HCV-related disease burden has been overlooked. This review provides a history of the fight against HCV, which has required scientists to avail themselves to the best of modern biomedical technology, which in turn has enriched our knowledge of virology and cellular physiology. == INTRODUCTION == The hepatitis C virus (HCV) is an enveloped, single-stranded, positive-sense RNA virus, classified as aHepaciviruswithin theFlaviviridaefamily[1-3]. The 9.6-kb RNA genome contains one long open reading frame (ORF) flanked by 5 and 3 untranslated regions (UTR)[4-6]. The single ORF encodes an approximately 3000 amino acid (aa) polyprotein that undergoes co- and post-translational cleavage by host and viral proteases to yield 10 viral proteins, not including the F protein[7,8]. The structural proteins, nucleic acid-binding nucleocapsid core protein and envelope proteins (E1 and E2/P7) are encoded by 25% of the N-terminal portion of the genome[9]. The remaining 75% of the genome encodes the non-structural proteins, NS2, NS3, NS4A, NS4B, NS5A Tarafenacin D-tartrate and NS5B[9]. Humans are the primary reservoir of HCV[10]. HCV transmission occurs primarily through exposure to infected blood and the majority of individuals with persistent infection develop chronic hepatitis, which can progress to cirrhosis or hepatocellular carcinoma[11-13]. Different from other viruses, such as influenza A viruses and human immunodeficiency Tarafenacin D-tartrate viruses, HCV is difficult to isolate and culture[14-16]. Since HCV was identified in 1989[1], basic research on HCV has been being hindered by the absence of reliable, reproducible, and efficient culture systems[11]. Recently, tremendous advances in understanding the HCV replicon[15,16], the pseudo-typed HCV viral particle[17], cell based culture systems[18,19], receptors[20-24], life cycle[25,26], structural biology and HCV therapy strategy[27-29] have been gained. However, several scotomas in the molecular virology and epidemiology of HCV remain to be elucidated. This review summarizes the advancements and remaining scotomas in the molecular virology and epidemiology of HCV. == MAJOR PROGRESS IN FIGHTING HCV == Since HCV was identified in 1989[1], virological research has led to a great deal of progress in the pathogenesis, diagnosis, treatment, control and prevention of the disease[11,30]. Since virus elimination is the ultimate goal of viral disease therapy, here we emphasize two major recent achievements in hepatitis C treatment. The first achievement was the development of direct-acting antiviral (DAA) agents, which are inhibitors of the HCV protease[31-37]. Although peginterferon and ribavirin remain vital components of therapy, the emergence of DAA agents has led to an unprecedented improvement in sustained virologic response rates to approximately 94%[30,38]. This is indicative of two milestones in virology:.